Search clinical trials for: Simvastatin 20 mg Ezetimibe 10 mg and Simvastatin 40 mg Ezetimibe 10 mg, according to clinical e

Total 366 results

Ache Laboratorios Farmaceuticos S.A.

Completed

Efficacy/Safety of Rosuvastatin+Ezetimibe in High Risk Patients With Primary Hypercholesterolemia/Mixed Dyslipidemia (LANCE)

Dyslipidemia | Hypercholesterolemia

Brazil
Organon and Co
Merck Shering-Plough JV Study

Completed

A Study to Assess the Cholesterol Lowering Effect of Ezetimibe/Simvastatin Combination Tablet Compared to Another Cholesterol Lowering Drug in Elderly Patients With High Cholesterol at High or Moderately High Risk for Coronary Heart Disease (0653A-128)

Hypercholesterolemia
Hue University of Medicine and Pharmacy
Università degli Studi di Sassari

Unknown

Lipid-lowering Therapies in Vietnamese Chronic Kidney Disease Population (VietCKD)

Chronic Kidney Diseases | Hypercholesterolemia

Vietnam
Organon and Co
Schering-Plough

Completed

The Effects of Ezetimibe/Simvastatin 10/20 mg Versus Simvastatin 40 mg in High Cholesterol and Coronary Heart Disease Study (P04039AM2)(COMPLETED)

Coronary Disease | Hypercholesterolemia
Organon and Co

Completed

IMPROVE-IT: Examining Outcomes in Subjects With Acute Coronary Syndrome: Vytorin (Ezetimibe/Simvastatin) vs Simvastatin (P04103)

Myocardial Infarction | Hypercholesterolemia
University of Ioannina

Completed

Comparison of Simvastatin Versus Simvastatin/Ezetimibe on Small Dense Low -Density Lipoprotein (LDL)

Hypercholesterolemia

Greece
University Hospital Freiburg
Essex Pharma GmbH

Completed

Effect of Ezetimibe or Simvastatin or Both on Low Densitiy Lipoprotein -Subfractions in Patients With Type 2 Diabetes (EZE)

Hypercholesterolemia | Diabetes Mellitus Type 2

Germany
Organon and Co

Completed

Ezetimibe/Simvastatin (10 mg/40 mg) vs. the Doubling of Atorvastatin in High Risk Participants (MK-0653A-134 AM1)(COMPLETED)

Hypercholesterolemia
Organon and Co
Schering-Plough

Completed

Ezetimibe and Simvastatin in Primary Hypercholesterolemia, Diabetes Mellitus Type 2, and Coronary Heart Disease (COMPLETED)

Coronary Disease | Diabetes Mellitus, Type 2 | Hypercholesterolemia
Organon and Co

Completed

Ezetimibe/Simvastatin (MK-0653A) Versus Rosuvastatin Versus Doubling Statin Dose in Participants With Cardiovascular Disease and Diabetes Mellitus (MK-0653A-133)(COMPLETED)

Diabetes Mellitus | Cardiovascular Disorder
Instituto Nacional de Ciencias Medicas y Nutricion...
Merck Sharp & Dohme LLC

Withdrawn

Efficacy of Ezetimibe/Simvastatin 10/20 mg and MK0524A (1-2 g/Day) in Mixed Hyperlipidemia and Two or More Risk Factors

Cardiovascular Diseases | Hyperlipidemia
University of Sao Paulo

Completed

Antiplatelet and Anti-inflammatory Effects of Statins and Ezetimibe

Stable Angina

Brazil
Merck Sharp & Dohme LLC

Completed

A Randomized, Double-Blinded Study of Simvastatin 20 mg/Day Versus Vytorin 10/20 in Subjects With Lipid Profiles Not Meeting Current NCEP Guidelines, Following a Low-Carbohydrate Diet (LOCUST)

Hyperlipidemia
Organon and Co

Completed

A Study of Ezetimibe Added On to Rosuvastatin Versus Up Titration of Rosuvastatin in Patients With Hypercholesterolemia (MK0653-139)

Hypercholesterolemia
Organon and Co

Completed

An Efficacy and Safety Study of Ezetimibe (MK-0653, SCH 58235) in Addition to Atorvastatin Compared to Placebo in Participants With Primary Hypercholesterolemia (MK-0653-013)

Hypercholesterolemia
Abbott

Completed

A 12-week Study to Compare the Efficacy and Safety of Fixed Combinations of Fenofibrate/Simvastatin 145/20mg and Fenofibrate/Simvastatin 145/40mg Tablets Versus Fenofibrate or Simvastatin Monotherapies in Subjects With Abnormal Blood Levels of Fats (Lipids) and at High Risk of Cardiovascular Disease

Dyslipidemia

Argentina, Czech Republic, Germany, Mexico, Poland, Romania, Russian Federation
Organon and Co

Completed

A Clinical Trial to Assess the Efficacy and Safety of MK-0653C in Japanese Participants With Hypercholesterolemia (MK-0653C-383)

Hypercholesterolemia
University of Oxford
National Health and Medical Research Council, Australia; Merck Sharp & Dohme... and other collaborators

Completed

Study of Heart and Renal Protection (SHARP)

Kidney Disease, Chronic

United Kingdom
Samsung Medical Center
Hanmi Pharmaceutical co., ltd.

Active, not recruiting

Usual Dose Rosuvastatin Plus Ezetimibe Versus High-dose Rosuvastatin on Coronary Atherosclerotic Plaque (Rosuzet-IVUS)

Coronary Artery Disease

Korea, Republic of
Canadian Network for Observational Drug Effect...
Canadian Institutes of Health Research (CIHR); Drug Safety and Effectiveness...

Completed

High Potency Statins and Acute Kidney Injury

Hypercholesterolemia

Canada
Canadian Network for Observational Drug Effect...
Canadian Institutes of Health Research (CIHR); Drug Safety and Effectiveness...

Completed

High Potency Statins and the Risk of Diabetes (Statins-DM)

Cardiovascular Disease | Diabetes Mellitus, Type 2
Bronx VA Medical Center

Completed

Evaluation of LDL Cholesterol in Patients Switched From 10 to 5 Milligrams of Zetia (Ezetimibe)

Hypercholesterolemia

United States
H. Lundbeck A/S

Completed

Bioequivalence Study of Lu AF35700

Healthy

United Kingdom
Janssen-Cilag International NV

Completed

A Study to Investigate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of JNJ-42847922 in Healthy Participants

Healthy

Germany
Seoul National University Hospital
Gangnam Severance Hospital

Recruiting

Efficacy and Safety of EzetimiBe/Rosuvastatin in Diabetic Dislipidemia With Hypertriglyceridaemia (REMBRANDT)

Diabetes Mellitus, Type 2 | Endocrine System Diseases | Dyslipidemias | Nutritional and Metabolic Diseases

Korea, Republic of
Stanford University
AstraZeneca; Ligand Pharmaceuticals

Completed

A Phase I/II Study of Bexarotene in Combination With ZD1839 (IRESSA®) in the Treatment of Non-Small Cell Lung Cancer

Lung Cancer

United States
Bioprojet

Completed

Dose Range Finding Study of BF2.649 Versus Placebo to Treat Excessive Daytime Sleepiness in Parkinson's Disease Patients

Parkinson's Disease | Excessive Daytime Sleepiness

France
Cytokinetics
Ji Xing Pharmaceuticals (Shanghai) Co., Ltd.

Completed

Phase 3 Trial to Evaluate the Efficacy and Safety of Aficamten Compared to Placebo in Adults With Symptomatic oHCM (SEQUOIA-HCM) (SEQUOIA-HCM)

Obstructive Hypertrophic Cardiomyopathy (oHCM)

United States, France, Spain, Portugal, Germany, China, United Kingdom, Israel, Netherlands, Denmark, Czechia, Hungary, Italy, Poland
Organon and Co

Completed

Retrospective Survey Evaluating the Effectiveness and Safety of Dual Inhibition Lipid-lowering in the Treatment of Dyslipidemia (Study P05171)(COMPLETED)

Dyslipidemia
NewAmsterdam Pharma

Not yet recruiting

A CCTA Imaging Trial to Evaluate the Effect of Obicetrapib/Ezetimibe on Coronary Plaque (REMBRANDT)

Coronary Artery Disease | Plaque, Atherosclerotic | Lipidemia
University at Buffalo
Kaleida Health

Completed

To Study the Effect of Vytorin on Intracellular Lipid and Inflammation in Obese Subjects

Inflammation

United States
Janssen Research & Development, LLC

Completed

A Study to Assess the Effects of Age and Gender on the Pharmacokinetics of JNJ-42847922 in Healthy Adults

Healthy

United States
Boehringer Ingelheim

Completed

A Study in Healthy Men to Test How Different Doses of BI 474121 Are Taken up and How They Influence the Amount of a Molecular Messenger (cGMP) in the Spinal Fluid

Healthy

Netherlands
Reata, a wholly owned subsidiary of Biogen
AbbVie

Completed

RTA 408 Capsules in Patients With Mitochondrial Myopathy - MOTOR

MItochondrial Myopathies

United States, Denmark
University of Roma La Sapienza

Unknown

Low-dose Statins and Nutraceuticals in High-intensity Statin-intolerant Patients (ADHERENCE)

Coronary Artery Disease

Italy
Suzhou Transcenta Therapeutics Co., Ltd.

Completed

A Phase I Study of MSB2311 in Advanced Solid Tumors

Advanced Solid Tumors

United States
Intermountain Health Care, Inc.
Merck Sharp & Dohme LLC; Abbott

Completed

Diabetes and Combined Lipid Therapy Regimen (DIACOR) Study

Type II Diabetes Mellitus | Mixed Dyslipidemia

United States
Impax Laboratories, LLC

Completed

IPX056 in Subjects With Established Spasticity Resulting From Multiple Sclerosis

Multiple Sclerosis

United States, Canada, Estonia, Latvia, Ukraine
Akros Pharma Inc.

Completed

Safety and Efficacy Study of JTT-705 in Combination With Simvastatin 40 mg in Patients With Low High-Density Lipoprotein (HDL) Levels

Dyslipidemia

Netherlands
Healthgen Biotechnology Corp.

Recruiting

Study of OsrhAAT or Placebo in Healthy Volunteers

Emphysema Secondary to Congenital AATD

United States
Esperion Therapeutics, Inc.

Completed

Milk-Only Lactation Study to Evaluate the Concentration of Bempedoic Acid and Bempedoic Acid/Ezetimibe Fixed Combination Drug Product (FCDP) in the Breast Milk of Healthy Lactating Women

Healthy Lactating Women

United States
NeuroActiva, Inc.

Completed

A Double-Blind, Placebo-Controlled Safety and Efficacy Study of NA-831

Neurocognitive Disorders | Neurodegenerative Diseases | Cognitive Impairment | Alzheimer Disease | Tauopathies | Mild Cognitive Impairment | Dementia, Vascular | Dementia With Lewy Bodies | Alzheimer Dementia | Cognitive Disorder

New Zealand
Organon and Co

Completed

A Clinical Trial to Assess the Long Term Safety and Tolerability of MK-0653C in Japanese Participants With Hypercholesterolemia (MK-0653C-384)

Hypercholesterolemia | Heterozygous Familial Hypercholesterolemia
Suzhou Transcenta Therapeutics Co., Ltd.

Completed

A Study of MSB2311 in Advanced Solid Tumors

Advanced Solid Tumor

China
Solvay Pharmaceuticals

Completed

A Controlled-Study of Fenofibrate 145 mg and Ezetimibe 10 mg in Type IIb Dyslipidemic Patients With Features of the Metabolic Syndrome

Hyperlipidemia Combined

Belgium, France, Germany
Eisai Co., Ltd.

Completed

A Study of APD356 (Lorcaserin) in Healthy Japanese Adult Subjects

Healthy Subjects

Japan
Reata, a wholly owned subsidiary of Biogen
AbbVie; Friedreich's Ataxia Research Alliance

Active, not recruiting

RTA 408 Capsules in Patients With Friedreich's Ataxia - MOXIe

Friedreich Ataxia

United States, Australia, Austria, Italy, United Kingdom
Sunnybrook Health Sciences Centre
Merck Frosst Canada Ltd.; Schering-Plough

Terminated

INdians Followed for INtensive Lipid Lowering Treatment and Its safetY (INFINITY)

Hypercholesterolemia

Canada
Breath of Life International Pharma Ltd

Completed

A Phase I Open Label Study to Assess PK and Safety of Plant Cannabis Extract

Healthy

Israel
Wyeth is now a wholly owned subsidiary of Pfizer

Terminated

Observational Study Analyzing RNA Expression Of Endometrial Biopsy Samples From Placebo, Bazedoxifene/Conjugated Estrogens And Raloxifene

Postmenopause

United States

3

Subscribe